Tocilizumab is a recombinant humanized monoclonal antibody developed against soluble and membrane-bound isoforms of the interleukin-6 [IL-6] receptor. It prevents the binding of IL-6 to its receptor, thus inhibiting the IL-6 inflammatory cascade [1]. In the first phase of the severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2] pandemic [2,3], tocilizumab has been proposed to counteract the cytokine release syndrome observed in the severe forms of the SARS-CoV-2 disease [COVID-19] [1,4].